IL17A and psoriasis: EULAR recommendations (Gossec et al., 2020) suggest a preferred option for an anti-IL-17A or anti-IL-12/23 agent over TNFis and JAKis in cases with severe skin involvement, while the 2015 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines tried to enlist specific treatments for individual clinical domains (e.g., axial, enthesis, dactylitis, and peripheral joint) and in cases with selected comorbidities (Ogdie et al., 2020).